Bogyo M, Wang E W
Department of Biochemistry and Biophysics, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, USA.
Curr Top Microbiol Immunol. 2002;268:185-208. doi: 10.1007/978-3-642-59414-4_8.
As the dominant protease dedicated to protein turnover, the proteasome shapes the cellular protein repertoire. Our knowledge of proteasome regulation and activity has improved considerably over the past decade. Novel inhibitors, in particular, have helped to advance our understanding of proteasome biology. They range from small peptide-based structures that can be modified to vary target specificity, to large macromolecular inhibitors that include proteins. While these reagents have played an important role in establishing our current knowledge of the proteasome's catalytic mechanism, many questions remain. Rapid advances in the synthesis and identification of new classes of proteasome inhibitors over the last 10 years serve as a positive indicator that many of these questions will soon be resolved. The future lies in designing compounds that can function as drugs to target processes involved in disease progression. It may only be a short while before the products of such research have safe application in a practical setting. Structural and combinatorial chemistry approaches are powerful techniques that will bring us closer to these goals.
作为负责蛋白质周转的主要蛋白酶,蛋白酶体塑造了细胞蛋白质库。在过去十年中,我们对蛋白酶体调节和活性的了解有了显著提高。特别是新型抑制剂,有助于推动我们对蛋白酶体生物学的理解。它们的范围从可进行修饰以改变靶标特异性的基于小肽的结构,到包括蛋白质的大型大分子抑制剂。虽然这些试剂在确立我们目前对蛋白酶体催化机制的认识方面发挥了重要作用,但仍有许多问题存在。过去10年中新型蛋白酶体抑制剂合成和鉴定方面的快速进展是一个积极迹象,表明其中许多问题很快将得到解决。未来在于设计能够作为药物靶向参与疾病进展过程的化合物。也许不久之后,此类研究的成果就能在实际应用中安全使用。结构化学和组合化学方法是强大的技术,将使我们更接近这些目标。